Overview
| 别名 | Methyl-CpG-binding domain protein 5; Methyl-CpG-binding protein MBD5 |
| 基因名 | MBD5 |
| UniProt ID | Q9P267 |
| 反应种属 | Human |
| 应用 | WB |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 9A4-D7-F5 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 159 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:4000 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Methyl-CpG binding domain protein 5 (MBD5) is a nuclear chromatin-associated protein belonging to the MBD family, characterized by an N-terminal methyl-CpG binding domain and a central PWWP domain. Although it contains a structural motif related to methyl-DNA binders, MBD5 functions primarily as a transcriptional regulator and neuronal differentiation factor rather than a canonical methyl-CpG binding protein. It associates with the PR-DUB deubiquitinase complex to modulate gene expression at active chromatin sites marked by H3K4me1/3 and H3K27ac. MBD5 is widely expressed with significant enrichment in the brain, where it plays a vital role in chromatin organization and neurodevelopment. Clinically, haploinsufficiency or disruptive variants of MBD5 are the established cause of MBD5-associated neurodevelopmental disorder, also known as 2q23.1 deletion syndrome. This condition is characterized by intellectual disability, severe speech impairment, autistic features, seizures, and distinct craniofacial dysmorphism. |
检测原理